Glucotrack raises $4.0M via private placement of pre-funded and common warrants

Glucotrack, Inc.

Gross proceeds ~$4.0M from sale of 1,033,591 pre-funded warrants and 2,067,182 common warrants at $3.87/unit.
Common warrants exercise price $3.87, not exercisable until stockholder approval, expire 5 years after approval.
Net proceeds for working capital and general corporate purposes.
Officers and directors entered 90-day lock-up agreements restricting share transfers.
Curvature Securities acted as sole placement agent; receives 7% cash fee and warrants for 124,030 shares at $4.257.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Glucotrack, Inc. entered into Securities Purchase Agreement with an investor valued at approximately $4.0 million (effective 2025-12-29).

Action: entry
Agreement: equity purchase
Counterparty: an investor
Value: approximately $4.0 million
Effective: 2025-12-29

Exact text from the filing

On December 29, 2025, Glucotrack, Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with an investor (the “Investor”) for a private placement of securities

View on SEC.gov

329 material agreements filed in the last 30 days. Browse all material agreements →

Glucotrack, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-25-029791

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.